Alcohol Abuse: Clinical Trials

15 trials for Alcohol Abuse, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

13 completed, 1 terminated, 1 unknown. 15 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 415Completed 13, Terminated 1, Unknown 1

Follow Alcohol Abuse: new trials by email Literature Review of Alcohol Abuse trials Research Report on Alcohol Abuse

Trials (filtered) newest first · largest first

All 15 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Study of Ligustrazine in Treating Alcohol Addiction
Ligustrazine by intravenously administration, Ligustrazine by mouth, Placebo by intravenously administration - Alcohol Abuse, Arteriosclerosis
Phase 4UnknownShenzhen Kangning Hospital4002023-07-282023-10-16
Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT)
Isoniazid 300 Mg ORAL TABLET, Pyridoxine 25 Mg Oral Tablet - Tuberculosis, HIV/AIDS
Phase 4CompletedUniversity of California, San Francisco3022017-04-072023-10-19
Dutasteride Treatment for the Reduction of Heavy Drinking in Men
Dutasteride, sugar pill - Alcoholism, Alcohol Abuse
Phase 4CompletedUConn Health1892013-01-012019-04-26
Varenicline in Drug Treatment
varenicline, placebo - Smoking Cessation, Alcohol Abuse
Phase 4CompletedCentre for Addiction and Mental Health332011-06-012015-02-05
Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake
Parafon Forte - Alcohol Abuse
Phase 4CompletedUniversity of California, San Francisco482011-04-012020-11-20
Dutasteride for the Reduction of Alcohol Use in Male Drinkers
Dutasteride, Placebo - Alcoholism, Alcohol Abuse
Phase 4CompletedUConn Health472011-01-012017-03-20
Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy
Topiramate, Placebo administration - PTSD, Alcohol Abuse
Phase 4CompletedUniversity of California, San Francisco302010-04-012014-06-03
Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults
quetiapine and placebo, Quetiapine and Topiramate - Bipolar Disorder, Alcohol Abuse
Phase 4CompletedUniversity of Cincinnati562008-04-012017-05-23
Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism
acamprosate, escitalopram, Medical management - Major Depressive Disorder, Alcohol Abuse
Phase 4CompletedMassachusetts General Hospital232007-03-012012-07-09
Zonisamide vs. Placebo in the Treatment of Alcohol Dependence
zonisamide, Placebo - Alcoholism, Alcohol Abuse
Phase 4CompletedUConn Health402006-07-012010-10-15
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
Risperidone Long Acting, oral risperidone - Schizophrenia, Psychotic Disorders
Phase 4CompletedDartmouth-Hitchcock Medical Center952005-09-012019-05-09
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
Quetiapine - Schizophrenia, Schizoaffective Disorder
Phase 4CompletedDartmouth-Hitchcock Medical Center232004-03-012018-03-14
Naltrexone Treatment of Alcohol Abuse in Schizophrenia
Naltrexone or Placebo - Schizophrenia, Mental Disorders
Phase 4CompletedState University of New York - Upstate Medical University902003-04-012013-01-08
Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
Paroxetine, Placebo - Social Anxiety Disorder, Social Phobia
Phase 4CompletedMedical University of South Carolina422002-03-012018-09-27
Alcoholism and Schizophrenia: Effects of Clozapine
Clozapine versus typical (conventional) and atypical antipsychotic medications - Schizophrenia, Dual Diagnosis
Phase 4TerminatedDartmouth-Hitchcock Medical Center641999-05-012018-03-14

Narrower conditions

Alcoholism (15)  ·  Schizophrenia (4)  ·  Psychotic Disorders (3)  ·  Substance-Related Disorders (3)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Alcohol-Related Disorders (1)  ·  Arteriosclerosis (1)  ·  Behavior, Addictive (1)  ·  Bipolar Disorder (1)  ·  Depressive Disorder, Major (1)  ·  Mental Disorders (1)  ·  Phobia, Social (1)  ·  Smoking Cessation (1)  ·  Stress Disorders, Post-Traumatic (1)  ·  Tuberculosis (1)

Broader conditions

Chemically-Induced Disorders (15)  ·  Alcohol-Related Disorders (14)  ·  Mental Disorders (14)  ·  Substance-Related Disorders (12)  ·  Schizophrenia Spectrum and Other Psychotic Disorders (4)  ·  Behavior (2)  ·  Mood Disorders (2)  ·  Actinomycetales Infections (1)  ·  Anxiety Disorders (1)  ·  Arterial Occlusive Diseases (1)  ·  Bacterial Infections (1)  ·  Bacterial Infections and Mycoses (1)  ·  Bipolar and Related Disorders (1)  ·  Blood-Borne Infections (1)  ·  Cardiovascular Diseases (1)

Interventions

Sugars (3)  ·  Dutasteride (2)  ·  Quetiapine Fumarate (2)  ·  Topiramate (2)  ·  Acamprosate (1)  ·  Chlorzoxazone (1)  ·  Congresses as Topic (1)  ·  Escitalopram (1)  ·  Isoniazid (1)  ·  Lactose (1)  ·  Naltrexone (1)  ·  Paroxetine (1)  ·  Practice Management, Medical (1)  ·  Pyridoxine (1)  ·  Qnexa (1)

Sponsors

Dartmouth-Hitchcock Medical Center (3)  ·  UConn Health (3)  ·  University of California, San Francisco (3)  ·  Centre for Addiction and Mental Health (1)  ·  Massachusetts General Hospital (1)  ·  Medical University of South Carolina (1)  ·  Shenzhen Kangning Hospital (1)  ·  State University of New York - Upstate Medical University (1)  ·  University of Cincinnati (1)

Countries

United States (12)  ·  Canada (1)  ·  China (1)  ·  Uganda (1)

Top investigators

Alan I Green, MD (2)  ·  Alan I. Green, MD (1)  ·  Albert J. Arias, MD (1)  ·  Carrie L Randall, PhD (1)  ·  Howard Fields, PhD (1)  ·  Janet M Witte, MD (1)  ·  Jonathan Covault, M.D., PhD. (1)  ·  Jonathan Covault, MD, PhD (1)  ·  Judith A Hahn, PhD, MA (1)  ·  Laurie Zawertailo, PhD (1)  ·  Melissa P DelBello, MD (1)  ·  Nicholas Bolo, PhD (1)  ·  Steven L Batki, MD (1)  ·  Steven L. Batki, MD (1)  ·  Xiaojian Jia (1)

Results publications

PMID 23131884, PMID 26302441, PMID 36044285, PMID 38684046

NIH funding

P60AA003510 (2), M01RR006192 (1), P50AA003510 (1), R01AA013379 (1), R01AA013655 (1), R21AA016372 (1)